The Wegovy Pill Is Here: What You Need to Know About This Weight-Loss Breakthrough

The Food and Drug Administration has approved the first oral glucagon-like peptide-1 (GLP-1) pill for weight loss, marking a major milestone in obesity treatment. Novo Nordisk's Wegovy pill achieved 16.6% weight loss in clinical trials, matching the effectiveness of weekly injections while offering the convenience of a daily tablet.

How Effective Is the Wegovy Pill Compared to Injections?

The oral version delivers impressive results that rival its injectable counterpart. In the OASIS 4 trial involving 307 adults with obesity or overweight conditions, participants taking the highest 25-milligram dose lost an average of 16.6% of their body weight after 64 weeks, compared to just 2.7% weight loss in the placebo group. For comparison, injectable Wegovy showed up to 17.4% weight reduction in previous trials.

"The pill is here. With today's approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection," said Mike Doustdar, president and CEO of Novo Nordisk.

What Are the Key Differences Between Pills and Injections?

The oral version comes with both advantages and challenges that patients should understand:

• Convenience Factor: Pills eliminate the need for weekly self-injections, making treatment more psychologically acceptable for many patients who find needles intimidating
• Dosing Requirements: The pill must be taken daily on an empty stomach with no more than 4 ounces of water, and nothing else can be consumed for at least 30 minutes afterward
• Higher Doses Needed: Because the body breaks down the pill in the stomach, oral doses must be much higher than injections - up to 25 milligrams daily versus 2.4 milligrams weekly for injections
• Cost Considerations: The starting 1.5-milligram dose will cost $149 per month out of pocket, though higher effective doses may cost significantly more

"The oral option could improve long-term adherence by offering patients a non-injectable alternative with similar metabolic benefits," said Dr. W. Timothy Garvey, professor at the University of Alabama at Birmingham and a lead researcher for the oral semaglutide clinical trial.

When Will the Wegovy Pill Be Available?

Novo Nordisk plans to launch the once-daily oral semaglutide in United States pharmacies and select telehealth providers in early January 2026. The company has boosted production in preparation for the launch to avoid the prolonged shortages that plagued the injectable version when it first became available.

The approval creates competition in the emerging oral weight-loss market, as Eli Lilly's competing pill, orforglipron, is expected to receive FDA approval by March 2026. This increased competition could drive down prices and provide more options for patients struggling with obesity and related health conditions.

Side effects remain similar to the injectable version, with gastrointestinal issues like nausea, diarrhea, and vomiting being the most common complaints. However, some patients may experience more intense nausea because the medication hits the stomach all at once rather than being gradually absorbed like an injection.